Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon ...

Pfizer sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the ...

(Bloomberg) -- Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating a years-long separation from the maker of Sensodyne ...

Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each. The ...

Haleon has gained full control of its Chinese joint venture after acquiring Tianjin Pharmaceutical Da Ren Tang's 12% stake.

(Reuters) -Pfizer will sell its remaining stake in British consumer healthcare group Haleon, the companies said on Tuesday. Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon ...

Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

In a notice to the London Stock Exchange, Pfizer (PFE) announced that it intends to sell, in aggregate, approximately 662M ordinary shares in Haleon plc (HLN), representing approximately 7.3% of ...

Pfizer has completing its full exit from Weybridge-headquartered health firm Haleon. Haleon has agreed to an off-market purchase of 44,155,844 ordinary shares of £0.01 each from Pfizer. The off-market ...